China set a CNY 3.5 trillion revenue goal for its pharmaceutical sector by 2030, while US policy aims to tie state Medicaid drug prices to international benchmarks under the GENEROUS model. Meanwhile, major dealmaking continued as Gujarat Themis Biosyn bought MicroBiopharm Japan for Rs 1,300 crore and LEO Pharma acquired dersimelagon from Tanabe Pharma for up to $435 million.
01Policy
China Sets Global Biopharma Expansion Goals in New Five-Year Plan
Mandated R&D spending thresholds and first-in-class quotas pivot Chinese drugmakers from low-cost manufacturing competitors into direct, state-backed rivals for global biotech market share.
China released its 15th Five-Year Plan for the pharmaceutical industry, targeting operating above CNY 3.5 trillion by 2030. The joint directive from the Ministry of Industry and Information Technology, the National Development and Reform Commission, and eight other agencies sets a 20 percent average annual growth rate for innovative drugs. The policy shifts state backing from scale manufacturing to high-end innovation, mandating that first-in-class drugs account for more than 25 percent of the global total by the end of the decade. Listed drugmakers must maintain an average R&D intensity of at least 10 percent annually, while the sector aims to produce at least five products with global annual sales exceeding $1 billion. The roadmap also establishes 50 pharmaceutical enterprises with annual revenue above CNY 10 billion and 20 industrial parks at the 100-billion-yuan scale. Strategic investments will target , quantum computing, brain-computer interfaces, and cell therapy as priority breakthroughs.
Gujarat Themis Biosyn Completes Acquisition of MicroBiopharm Japan
Funding fermentation capacity through heavy leverage tests whether high-margin API manufacturing can service substantial debt before new regulatory approvals yield incremental revenue.
Gujarat Themis Biosyn Limited completed its of MicroBiopharm Japan Co., Ltd. for a total consideration of JPY 21.5 billion, or roughly Rs 1,300 crore. The transaction was executed through Themis Biosyn Japan Limited, a wholly owned subsidiary funded by Rs 475 crore in and Rs 745 crore in loans, backed by an arranged loan facility of up to Rs 800 crore. The purchase brings three GMP-compliant manufacturing plants, precision fermentation platforms, and established client relationships into the Indian API manufacturer's . Management structured the buyout to be accretive while expanding non-current liabilities from Rs 32.37 crore to Rs 136.51 crore in FY26 to finance the growth strategy.
LEO Pharma Gains FDA Priority Review for Dersimelagon and Closes Tanabe Acquisition
FDA Priority Review validates LEO Pharma's acquisition-led expansion into rare dermatology, securing accelerated regulatory routing to monetize a high-margin, capped-payout specialty drug asset.
LEO Pharma secured Priority Review for its oral skin disease therapy dersimelagon and closed its of the drug from Tanabe Pharma. The Food and Drug Administration set a Prescription Drug User Fee Act date by the end of February 2027. LEO Pharma acquired worldwide rights to the drug for up to $435 million in upfront and near-term milestone payments, alongside tiered royalties on net sales. Dersimelagon is an investigational melanocortin 1 receptor agonist designed to treat erythropoietic protoporphyria and X-linked protoporphyria. The transaction expands LEO Pharma's late-stage rare dermatology without altering its previously issued 2026 financial outlook.
Benchmarking state Medicaid acquisition costs to international prices replaces formulaic statutory rebates with negotiated manufacturer price ceilings across state purchasing pools.
President Donald Trump announced Friday that all 50 states, Washington, D.C., and Puerto Rico will participate in the GENEROUS model to lower drug prices for state programs. More than two dozen pharmaceutical companies agreed to sell drugs to state Medicaid programs at prices available in peer countries under the initiative. The White House estimated in May that these drug pricing deals could save $529 billion over the next 10 years. Experts and policy advisors note that the true cost and savings are unclear because the content of the deals has not been made public.
Directly executing wet-lab protocols lets Anthropic validate AI-generated biology in-house while shielding pharmaceutical client relationships, turning biosecurity compliance into a proprietary moat against model-only competitors.
Techcrunch.com reports that Anthropic operates a wet biology lab in the Bay Area to run physical experiments using its models. Anthropic acquired the stealth AI biotech firm Coefficient Bio in April. The lab focuses on fundamental biology rather than drug discovery to avoid competing with pharmaceutical partners such as Novo Nordisk. Anthropic concurrently launched a Life Sciences Verification Program to grant vetted researchers access to its powerful models. CEO Dario Amodei recently published a post calling for industry self-regulation and has previously cited bioterrorism as a major risk of AI.
Ascension Sells Ownership Stake in Arizona Medicaid Plan to Aetna
Ascension divesting its Mercy Care stake to Aetna marks a retreat by health systems from co-owning insurance risk, leaving underwriting entirely to specialized managed care operators.
Healthcaredive.com reports that Ascension is selling its ownership stake in Mercy Care to CVS Health-owned Aetna. The divestiture allows the nonprofit hospital system to shed insurance risk while Aetna expands its presence in high- dual-eligible plans. Mercy Care covers approximately 404,000 members across and dually eligible programs in Arizona. Dignity Health, part of CommonSpirit, co-owned the managed care insurer alongside Ascension since its 1985 founding, though Aetna managed daily operations since 2002. Financial terms of the transaction were not disclosed. The sale remains subject to regulatory approval and lacks a finalized closing date.
Insurtech Startup Angle Health Reaches $2.7 Billion Valuation
Achieving profitability in small-business coverage demonstrates that integrating level-funded health plans directly into payroll systems solves the underwriting efficiency bottleneck that previously crippled digital health insurers.
According to techcrunch.com, health insurance startup Angle Health raised a $200 million Series C and a $400 million tender offer at a $2.7 billion . Vitruvian Partners led the round, with participation from Town Hall Ventures, Blumberg , Portage Ventures, PruVen Capital, and Y Combinator. The tender offer allows employees to cash out some of their shares, and the company expects the round to close later this month. Angle Health provides level-funded health plans for small businesses, operating as a platform that integrates with payroll and HR systems. The startup serves over 5,000 businesses and is profitable.
Surging cross-border acquisitions and state-backed revenue targets indicate strong commercial activity in pharmaceuticals. However, legislative shifts toward international price matching in US Medicaid plans leave long-term global drug pricing power unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.